Vanda Pharmaceuticals

vandapharma.com

Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

HOUSE RX TO LAUNCH SPECIALTY DRUG DISPENSING INSIDE RHEUMATOLOGY CLINICS BY PARTNERING WITH THREE LEADING PRACTICES

House Rx | August 04, 2022

news image

House Rx, the platform for medically integrated dispensing of specialty medications, announced it has partnered with three new rheumatology clinics to integrate in-house specialty drug dispensing – also known as medically integrated dispensing (MID) – into the clinics' operations. The three practices are: Arizona Arthritis & Rheumatology Associates (AARA), Arthritis & Osteoporosis Consultants of the Carolinas (AOCC), and Arthritis Associates of Tennessee and represent an ...

Read More

Business Insights

ANOKION ANNOUNCES $35 MILLION EQUITY INVESTMENT FROM PFIZER

Anokion | October 19, 2022

news image

Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative. In conjunction with the investment, Michael Vincent, M.D., Ph.D., senior vice president and chief scientific officer, Inflammation & Immunology, Pfizer, has joined the company’s scientific advisory board, which will be announced later thi...

Read More

Business Insights, PHARMACY MARKET

VISIOX PHARMA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR GLAUCOMA

Visiox Pharma LLC | December 09, 2022

news image

Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced that it has received notification from the U.S. Food and Drug Administration that the agency has completed its filing review and accepted for filing the New Drug Application for PDP-716 for the treatment of glaucoma. The FDA has assigned a Prescription Drug User ...

Read More

Pharmacy Market

CATALYST PHARMACEUTICALS ACQUIRES EXCLUSIVE NORTH AMERICAN LICENSE FOR VAMOROLONE FOR DUCHENNE MUSCULAR DYSTROPHY FROM SANTHERA PHARMACEUTICALS

Globenewswire | July 20, 2023

news image

Catalyst Pharmaceuticals, Inc. announced the completion of its acquisition from Santhera Pharmaceuticals Holdings of an exclusive license for North America for vamorolone, a potential treatment for patients suffering with Duchenne Muscular Dystrophy. The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Europe and Japan should Santhera pursue partnership opportunities. Additionally, Catalyst will hold North American rig...

Read More
news image

Pharma Tech

HOUSE RX TO LAUNCH SPECIALTY DRUG DISPENSING INSIDE RHEUMATOLOGY CLINICS BY PARTNERING WITH THREE LEADING PRACTICES

House Rx | August 04, 2022

House Rx, the platform for medically integrated dispensing of specialty medications, announced it has partnered with three new rheumatology clinics to integrate in-house specialty drug dispensing – also known as medically integrated dispensing (MID) – into the clinics' operations. The three practices are: Arizona Arthritis & Rheumatology Associates (AARA), Arthritis & Osteoporosis Consultants of the Carolinas (AOCC), and Arthritis Associates of Tennessee and represent an ...

Read More
news image

Business Insights

ANOKION ANNOUNCES $35 MILLION EQUITY INVESTMENT FROM PFIZER

Anokion | October 19, 2022

Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative. In conjunction with the investment, Michael Vincent, M.D., Ph.D., senior vice president and chief scientific officer, Inflammation & Immunology, Pfizer, has joined the company’s scientific advisory board, which will be announced later thi...

Read More
news image

Business Insights, PHARMACY MARKET

VISIOX PHARMA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR GLAUCOMA

Visiox Pharma LLC | December 09, 2022

Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced that it has received notification from the U.S. Food and Drug Administration that the agency has completed its filing review and accepted for filing the New Drug Application for PDP-716 for the treatment of glaucoma. The FDA has assigned a Prescription Drug User ...

Read More
news image

Pharmacy Market

CATALYST PHARMACEUTICALS ACQUIRES EXCLUSIVE NORTH AMERICAN LICENSE FOR VAMOROLONE FOR DUCHENNE MUSCULAR DYSTROPHY FROM SANTHERA PHARMACEUTICALS

Globenewswire | July 20, 2023

Catalyst Pharmaceuticals, Inc. announced the completion of its acquisition from Santhera Pharmaceuticals Holdings of an exclusive license for North America for vamorolone, a potential treatment for patients suffering with Duchenne Muscular Dystrophy. The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Europe and Japan should Santhera pursue partnership opportunities. Additionally, Catalyst will hold North American rig...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us